Ert Pompe denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Limits Quantity for Pompe Disease ERT — and Why You Can Fight It

Enzyme replacement therapy (ERT) for Pompe disease is a weight-based infusion therapy, meaning the amount dispensed each cycle is directly tied to the patient's body weight and the dosing interval specified in the FDA-approved prescribing label. Blue Cross Blue Shield plans frequently impose quantity limits that reflect a "standard" patient profile, and those limits can fall short of what a heavier patient — or a patient whose prescriber has documented clinical reasons for a dosing adjustment — actually requires.

This type of denial is strongly appealable because quantity limits must be grounded in the insurer's own published medical-policy criteria, and those criteria must themselves align with the approved labeling. When the quantity requested matches the label's weight-based formula, the insurer bears the burden of explaining the clinical rationale for restricting below label.

## Federal Appeal Rights

Under ACA Section 2719 and its implementing regulations, non-grandfathered group and individual plans must provide internal appeal and, if the denial is upheld, access to independent external review. ERISA Section 503 separately guarantees plan participants a full-and-fair review process with access to the specific plan criteria used to reach the adverse decision. External review must generally be requested within four months of the final internal denial, and an expedited track (typically 72 hours) is available when the standard timeline would seriously jeopardize health.

## What to Gather

• Current weight documentation — a recent measured weight from the clinical chart, along with the exact weight-based calculation matching the FDA label dose.
• Prescribing label excerpt — print or cite the dosing section of the approved prescriber information, showing the per-kg calculation and the approved interval.
• BCBS medical-policy printout — obtain the current version of the relevant coverage policy from BCBS's public policy library and identify every quantity criterion listed.
• Prescriber medical-necessity letter — the physician or metabolic specialist should state why the requested quantity is the medically necessary amount, anchored to the label and the patient's documented weight.
• Infusion administration records — prior infusion logs confirming weight at each visit and volumes actually administered.

## Criteria-Mapping Structure

Build a side-by-side table: left column lists each quantity criterion from the BCBS policy; right column answers each with the corresponding chart fact or label citation. If BCBS's limit is lower than the label-derived amount, that gap is the centerpiece of your appeal argument. Cite the FDA-approved labeling and the applicable metabolic-disease management guidelines (such as those from the relevant professional society for lysosomal storage disorders) to show that the requested quantity is the standard of care, not an outlier.

## Process and Timeline

1. Submit a written first-level internal appeal within the plan's deadline (typically 180 days from denial). 2. Attach all documentation above, organized per the criteria table. 3. If denied internally, request the external reviewer assignment within four months. 4. For patients currently receiving infusions, consider the expedited pathway to avoid a gap in treatment.